[Translation]

Novernber 30, 2022

To Shareholders

Company Name: Renascience Inc
Name of Representative: Koji Naito, President & CEO
(Code: 4889 TSE Growth)
Inquiries: Hiroyasu Ishimaru, Corporate Officer in charge
of Administration and Corporate Planning

Announcement of Conclusion of Memorandom of Understanding with NEC Solution Innovators, Ltd.

The Company hereby announces that the Company has decided to execute the Memorandom of Understanding (the "MOU") with NEC Solution Innovators, Ltd. ("NES") to pursue the joint activities to create innovations in the mtedical field with artificial intelligence (AI).

Although this matter does not meet the category of the timely disclosure as stipulated by the rules of the Tokyo Stock Exchange, the Company voluntarily discloses this information because it considers that the information is of value to the Shareholders.

1. Background of the MOU

   The Company conducts research and development of various modalities (pharmaceuticals, medical devices, and other forms of treatment) to solve medical issues. One of these is the development of the medical solutions using artificial intelligence (AI), and the Company has already started six medical projects. NES will be in charge of developing the system infrastructure to execute the AI developed by the Company in the medical field.

   With the MOU in place, we will capture the medical issues more broadly, resolve them in the medical field, and accelerate the creation of new medical value and innovation.

2. Contents of the MOU

   Based on the MOU, NEC Corporation will develop AI useful for medical treatment (diagnosis and treatment), and NES will aim to develop a system infrastructure to execute the developed AI in the medical fields.

   As a specific example, a project of the Company has been selected by the program of the Innovation in Medical Engineering Promotion Project (Development and Commercialization Project) of the Japan Agency for Medical Research and Development (AMED) in FY2022 to develop an AI to predict insulin dosage for diabetes patients. The NES technologies for the system integration and platform development will be utilized in this project. In the future, the Company plan to work with NES to develop more AI business in the medical fields, such as dialysis and dysphagia, which the Company has already studied.

3. Outlook for the future

   This matter will have no impact on the earning forecast for the fiscal year ending March 31, 2023.

End